Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul 23:7:129-38.
doi: 10.2147/DHPS.S50549. eCollection 2015.

Cardiovascular effects of hormone therapy for prostate cancer

Jason F Lester  1 , Malcolm D Mason  2
Affiliations
Review

Cardiovascular effects of hormone therapy for prostate cancer

Jason F Lester et al. Drug Healthc Patient Saf. .

Abstract

Androgen deprivation therapy (ADT) has been the mainstay of treatment for advanced prostate cancer for decades, and has been shown to control disease and improve symptoms. In addition, for men with high-risk localized or locally advanced prostate cancer, short-course ADT in combination with radiotherapy improves survival. There is evidence that ADT increases cardiovascular risk, particularly in men with preexisting cardiovascular disease. This increased risk may apply even with short-course ADT. In an individual patient, the benefits of ADT should be balanced against the risk, and patients who require ADT should have risk factors for cardiovascular disease optimized. There is some evidence to suggest that more contemporary methods of delivering ADT may reduce cardiovascular risk.

Keywords: androgen deprivation therapy; androgen receptor; cardiovascular risk; dihydrotestosterone; hypercoagulability; prostate cancer patients; testosterone.

PubMed Disclaimer

References

    1. Huggins CB, Hodges CV. Studies on prostate cancer: 1. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:2932–297. - PubMed
    1. Huggins C, Stevens RE, Jr, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209–223.
    1. Levine GN, D’Amico AV, Berger P, et al. American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;60(3):194–201. - PMC - PubMed
    1. Nguyen PL. Androgen-deprivation therapy and cardiovascular harm: let’s not throw out the baby with the bathwater. Eur Urol. 2014;65(4):710–712. - PubMed
    1. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010;11(11):1066–1073. - PubMed